The latest announcement is out from Lucid Diagnostics ( (LUCD) ).
On April 9, 2025, Lucid Diagnostics announced an underwritten public offering of its common stock, with Canaccord Genuity LLC as the sole bookrunner. The offering, priced at $1.20 per share, aims to raise approximately $15 million, with proceeds intended for working capital and general corporate purposes. The sale of 12,500,000 shares is expected to close around April 11, 2025, subject to customary closing conditions. The offering is made under an existing shelf registration statement, and the company has granted underwriters a 45-day option to purchase additional shares.
Spark’s Take on LUCD Stock
According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.
Lucid Diagnostics shows significant potential due to its strong revenue growth and recent strategic milestones, such as increased test volumes and insurance coverage. However, the company faces substantial financial challenges, including profitability issues and negative cash flows. Technical indicators suggest positive momentum, but the company’s negative P/E ratio and lack of dividends highlight ongoing financial and operational risks.
To see Spark’s full report on LUCD stock, click here.
More about Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer. Lucid’s products include the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device, designed for early detection of esophageal precancer.
YTD Price Performance: 108.86%
Average Trading Volume: 767,434
Technical Sentiment Signal: Strong Sell
Current Market Cap: $143.3M
For a thorough assessment of LUCD stock, go to TipRanks’ Stock Analysis page.